ARS Pharmaceuticals launched Neffy, the first FDA-approved needle-free epinephrine nasal spray for severe allergic reactions.

Confusion between approved injectable epinephrine products and unapproved nasal solutions has prompted a warning to ...

School administrators and nurses are encouraged to review applicable state laws and regulations to ensure neffy ® (epinephrine nasal spray) 2 mg for undesignated use meets applicable state law ...

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Get Free Report) has earned a consensus recommendation of “Buy” from the seven research firms that are currently covering the stock, Marketbeat Ratings reports ...

(epinephrine nasal spray) net product revenue for the fourth quarter and full year 2024 and outlined its 2025 commercial and clinical objectives. The preliminary results set forth above are unaudited, ...

neffyinSchools provides eligible public and private K-12 schools in the U.S. with the opportunity to receive two cartons (four single use doses) of neffy ® (epinephrine nasal spray) 2 mg for use ...

Detailed price information for Ars Pharmaceuticals Inc (SPRY-Q) from The Globe and Mail including charting and trades.